This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 1 for:    NCT02742844
Previous Study | Return to List | Next Study

Clinical Trial to Investigate Efficacy and Safety of the IMP in Patients With Non Healing Wounds Originating From Ulcers

This study is currently recruiting participants.
See Contacts and Locations
Verified May 2017 by Rheacell GmbH & Co. KG
Sponsor:
Collaborators:
TICEBA GmbH
FGK Clinical Research GmbH
Granzer Regulatory Consulting & Services
Information provided by (Responsible Party):
Rheacell GmbH & Co. KG
ClinicalTrials.gov Identifier:
NCT02742844
First received: April 7, 2016
Last updated: May 4, 2017
Last verified: May 2017
  Purpose
The aim of this clinical trial is to investigate the efficacy (by monitoring the wound size reduction) and safety (by monitoring occurring adverse events) of the investigational medicinal product APZ2 after one single application on chronic venous leg ulcer wounds.

Condition Intervention Phase
Skin Ulcer Venous Stasis Chronic Biological: APZ2 application Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: An Interventional, Single Arm, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of APZ2 on Wound Healing of Chronic Venous Ulcer (CVU)

Resource links provided by NLM:


Further study details as provided by Rheacell GmbH & Co. KG:

Primary Outcome Measures:
  • Percentage of wound size reduction [ Time Frame: Week 12 post baseline, or last available post-baseline measurement if the Week 12 measurement is missing ]
    Percentage of wound size reduction at Week 12, or last available post-baseline measurement if the Week 12 measurement is missing (last observation carried forward [LOCF])

  • Assessment of adverse event (AE) occurrence [ Time Frame: At biopsy removal, 1-3 days post biopsy, 7-10 days post biopsy, 6-12 weeks post biopsy; at baseline and days 3, 8 and weeks 2, 3, 4, 6, 8, 10, 12 and month 12 post baseline ]
    All during the clinical trial occurring AEs will be registered, documented and evaluated.


Secondary Outcome Measures:
  • Percentage of wound size reduction [ Time Frame: Weeks 2, 3, 4, 6, 8, 10 and 12 post baseline ]
    Percentage of wound size reduction at Weeks 2, 3, 4, 6, 8, 10 and 12 (without LOCF)

  • Absolute wound size reduction [ Time Frame: Weeks 2, 3, 4, 6, 8, 10, and 12 post baseline ]
  • Proportion of patients achieving complete wound closure [ Time Frame: Weeks 2, 3, 4, 6, 8, 10, and 12 post baseline and at any time point up to week 12 ]
  • Time to first complete wound closure [ Time Frame: Between baseline and week 12 post baseline ]
    A priori specification not possible

  • Proportion of patients achieving 30% wound closure [ Time Frame: Weeks 2, 3, 4, 6, 8, 10, 12 post baseline ]
  • Time to first 30% wound closure [ Time Frame: Between baseline and week 12 post baseline ]
    A priori specification not possible

  • Percentage of wound epithelialization [ Time Frame: At baseline and days 3, 8 and weeks 2, 3, 4, 6, 8, 10, 12 post baseline ]
    Amount of wound epithelialization in % of wound area will be assessed by the investigator based on image analysis of images taken from the wound.

  • Formation of granulation tissue and wound exudation [ Time Frame: At baseline and days 3, 8 and weeks 2, 3, 4, 6, 8, 10, 12 post baseline ]

    Formation of granulation tissue in % of wound area will be assessed by the investigator based on image analysis of images taken from the wound.

    Wound exudation will be classified by the investigator using following scores:

    • High: Small amounts of fluid or free fluids are visible when the dressing is removed; dressing is extensively marked or wet
    • Moderate: Small amounts of fluid are visible when dressing is removed; wound bed may appear glossy; Primary dressing may be lightly marked
    • Low: Wound bed is dry; there is no visible moisture; Primary dressing is unmarked; dressing may be adherent to wound

  • Pain assessment as per numerical rating scale (NRS) [ Time Frame: At baseline and days 3, 8 and weeks 2, 3, 4, 6, 8, 10, 12 post baseline ]
  • Quality of life (QoL) assessment using the SF-36 questionnaire [ Time Frame: At baseline and weeks 4, 8, 12 post baseline ]
  • Dermatologic quality of life assessment using the DLQI questionnaire [ Time Frame: At baseline and weeks 4, 8, 12 post baseline ]
  • Physical examination and vital parameters [ Time Frame: At Screening, baseline, week 12, month 12 ]

Estimated Enrollment: 37
Study Start Date: August 2016
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: APZ2 application
Topical, single application of APZ2; 500000 cells per square cm;
Biological: APZ2 application
Application of IMP on patients wound.

Detailed Description:

This is an interventional, single arm, phase I/IIa clinical trial to investigate the efficacy and safety of ABCB5+ mesenchymal stem cells (MSCs) on wound healing in patients with chronic venous ulcer (CVU). Autologous MSCs will be isolated ex vivo from a small skin biopsy and will be expanded in vitro. The IMP APZ2 incorporating the ABCB5+ will then be applied on the wound surface of CVU under local anesthesia.

Patients are followed up for efficacy for 3 months which allows to distinguish actual wound healing from transient wound coverage.

The wound healing process will be documented by standardized photography. The wound size evaluation will start on the day of the first change of wound dressing. The quality of the wound healing process will be assessed on the basis of formation of granulation tissue, epithelialization and wound exudation.

Pain will be assessed using a numerical rating scale and quality of life will be investigated with standardized and validated questionnaires. To assess long-term safety of APZ2 an additional follow-up visit at Month 12 post IMP application is included.

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female patients aged 18 to 85 years;
  2. Chronic venous leg ulcer (as defined by the current AWMF guidelines: therapy resistant ulcer that shows no improvement within 3 months despite of optimal phlebological therapies or is not healed within 12 months) for at least 6 weeks but shorter than 3 years diagnosed by doppler ultrasonography (DUS), ankle brachial index (ABI, 0.9-1.3), physical examination and dermatological review;
  3. Wound size between 5 and 50 square cm measured by a standardized photography at the screening visit;
  4. Wound location between knee and ankle;
  5. Patients suffering from 2 ulcers at the same extremity, as long as these ulcers are separated by a minimum bridge of 1 cm of epithelialized skin;
  6. Patients must agree to have at least one biopsy performed before treatment. In case IMP production from the first biopsy is not successful, a second biopsy will be taken;
  7. Body mass index (BMI) between 20 and 40 kg/m²;
  8. Patients understand the nature of the procedure and are providing written informed consent prior to any clinical trial procedure;
  9. Women of childbearing potential must have a negative blood pregnancy test at Screening and at Visit 5 before the IMP application;
  10. Women of childbearing potential and their partner must be willing to use highly effective contraceptive methods during the course of the clinical trial.

Exclusion Criteria:

General exclusion criteria

  1. Evidence of the ulcer extending to the underlying muscle, tendon, or bone;
  2. Current long-term use (more than 14 days) of steroid medication above Cushing-threshold dose (>7.5 mg/d prednisone or equivalent);
  3. Diabetes mellitus that has to be evaluated by blood test (Hemoglobin A1c [HbA1c] > 7.5%);
  4. Peripheral Artery Disease (PAD) including claudication;
  5. Acute deep vein thrombosis (maximum 30 days from diagnosis) or a still untreated deep vein thrombosis;
  6. Unable to tolerate leg ulcer compression bandage;
  7. Infection of the target ulcer requiring treatment as judged clinically;
  8. Wound size <1.5 cm² measured by a standardized photography at Visit 5;
  9. Any chronic dermatological disorders diagnosed at the investigator's discretion;
  10. Skin disorders, unrelated to the ulcer, that are present adjacent to the target wound;
  11. Current use of medications that influence wound healing: systemic immunosuppressives, cytotoxic medicinal products, and systemic steroids (above Cushing-threshold level);
  12. Known abuse of alcohol, drugs, or medicinal products;
  13. Cancerous or pre-cancerous lesions adjacent to the target wound;
  14. Patients anticipated to be unwilling or unable to comply with the requirements of the protocol;
  15. Pregnant or lactating women;
  16. Systemic infectious disease diagnosed by serology testing for syphilis (acute), human immunodeficiency virus (HIV˗1, HIV-2), hepatitis B (acute) or C infection at Screening or at Visit 2;
  17. Any known allergies to components of the IMP;
  18. Prior surgical procedures such as bypass or mesh-graft treatment within 2 months prior to IMP application;
  19. Treatment with active wound care agents (e.g. Iruxol, local antibiotics or silver dressings), which have not been paused 14 days before IMP application;
  20. Current or previous (within 30 days of enrollment) treatment with another IMP, or participation and/or under follow-up in another clinical trial;
  21. Previous participation in this clinical trial;
  22. Evidence of any other medical conditions (such as psychiatric illness, physical examination, or laboratory findings) that may interfere with the planned treatment, affect the patient's compliance, or place the patient at high risk of complications related to the treatment;
  23. Employees of the sponsor, or employees or relatives of the investigator.

Exclusion criteria for efficacy assessments

  1. A wound size enlargement of more than 25% between the wound assessment at the screening visit and the wound assessment at Visit 5;
  2. A wound size reduction of more than 50% between the wound assessment at the screening visit and wound assessment at Visit 5.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02742844

Contacts
Contact: Christoph Ganss, Dr. +49 6221 71833 ext 0 office@rheacell.com

Locations
Germany
Medizinische Fakultät Mannheim der Ruprecht-Karls-Universität Heidelberg; Universitätsklinikum Mannheim, Chirurgische Klinik Recruiting
Mannheim, Germany, 68167
Principal Investigator: Kay Schwenke, Dr.med.         
Klinik und Poliklinik für Allgemein- und Viszeralchirurgie, Gefäß- und Kinderchirurgie Zentrum Operative Medizin Recruiting
Würzburg, Germany, 97080
Principal Investigator: Martin Gasser, Prof.Dr.med.         
Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie Recruiting
Würzburg, Germany, 97080
Principal Investigator: Andreas Kerstan, PD Dr. med.         
Sponsors and Collaborators
Rheacell GmbH & Co. KG
TICEBA GmbH
FGK Clinical Research GmbH
Granzer Regulatory Consulting & Services
Investigators
Principal Investigator: Martin Gasser, Prof.Dr.med. Klinik und Poliklinik für Allgemein- und Viszeralchirurgie, Gefäß- und Kinderchirurgie Zentrum Operative Medizin
  More Information

Responsible Party: Rheacell GmbH & Co. KG
ClinicalTrials.gov Identifier: NCT02742844     History of Changes
Other Study ID Numbers: APZ2-II-01
Study First Received: April 7, 2016
Last Updated: May 4, 2017
Individual Participant Data  
Plan to Share IPD: Undecided

Keywords provided by Rheacell GmbH & Co. KG:
phase I/IIa
mesenchymal stem cells
ABCB5+
APZ2
chronic venous ulcer
varicose ulcer
skin ulcer
advanced therapy medicinal product
APZ2-II-01
autologous use
somatic cell therapy

Additional relevant MeSH terms:
Ulcer
Postphlebitic Syndrome
Postthrombotic Syndrome
Varicose Ulcer
Skin Ulcer
Pathologic Processes
Phlebitis
Peripheral Vascular Diseases
Vascular Diseases
Cardiovascular Diseases
Venous Insufficiency
Venous Thrombosis
Thrombosis
Embolism and Thrombosis
Varicose Veins
Leg Ulcer
Skin Diseases

ClinicalTrials.gov processed this record on June 23, 2017